News of the WeekPUBLIC HEALTH

U.S. Panel Favors Wider Use Of Preventive Drug Treatment

See allHide authors and affiliations

Science  08 Jan 2010:
Vol. 327, Issue 5962, pp. 130-131
DOI: 10.1126/science.327.5962.130

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

If regulators agree, the pool of people in the United States eligible for cholesterol-lowering drugs could soon expand dramatically to include as many as 6 million people whose cholesterol levels fall within a normal range. The potential boon to drugmakers and preventive health care came from an advisory committee to the U.S. Food and Drug Administration. The panel last month endorsed a wider use for Crestor, a statin manufactured by AstraZeneca. The decision, which could affect other statins too, raises tough questions: Who should get potentially risky medications to cut the chance of a deadly disease? And how many healthy people is it reasonable to treat to avoid one heart attack?